Heat shock protein 90 as a drug target: some like it hot - PubMed (original) (raw)
Review
Heat shock protein 90 as a drug target: some like it hot
Udai Banerji. Clin Cancer Res. 2009.
Abstract
Heat shock protein 90 (HSP90) is a ubiquitously expressed chaperone that is involved in the posttranslational folding and stability of proteins. Inhibition at the NH(2)-terminal ATP-binding site leads to the degradation of client proteins by the ubiquitin proteasome pathway. Inhibition of HSP90 leads to the degradation of known oncogenes, such as ERB-B2, BRAF, and BCR-ABL, leading to the combinatorial blockade of multiple signal transduction pathways, such as the RAS-RAF-mitogen-activated protein/extracellular signal-regulated kinase kinase-extracellular signal-regulated kinase and phosphatidylinositol 3-kinase pathways. Multiple structurally diverse HSP90 inhibitors are undergoing early clinical evaluation. The clinical focus of these drugs should be solid tumors, such as breast, prostate, and lung cancers, along with malignant melanoma, in addition to hematologic malignancies, such as chronic myeloid leukemia and multiple myeloma. HSP90 inhibitors can be used as single agents or in combination with other targeted treatments or conventional forms of treatment such as chemotherapy and radiotherapy. Clinical trials evaluating efficacy of these agents should include innovative designs to capture cytostasis evidenced by clinical nonprogression and enrichment of patient populations by molecular characterization. The results of clinical trials evaluating the efficacy of drugs targeting this exciting target are awaited.
Similar articles
- Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors.
Powers MV, Workman P. Powers MV, et al. Endocr Relat Cancer. 2006 Dec;13 Suppl 1:S125-35. doi: 10.1677/erc.1.01324. Endocr Relat Cancer. 2006. PMID: 17259553 Review. - Tanespimycin: the opportunities and challenges of targeting heat shock protein 90.
Erlichman C. Erlichman C. Expert Opin Investig Drugs. 2009 Jun;18(6):861-8. doi: 10.1517/13543780902953699. Expert Opin Investig Drugs. 2009. PMID: 19466875 Review. - Heat shock protein 90: a unique chemotherapeutic target.
Cullinan SB, Whitesell L. Cullinan SB, et al. Semin Oncol. 2006 Aug;33(4):457-65. doi: 10.1053/j.seminoncol.2006.04.001. Semin Oncol. 2006. PMID: 16890800 Review. - Inhibition of cancer invasion and metastasis by targeting the molecular chaperone heat-shock protein 90.
Koga F, Kihara K, Neckers L. Koga F, et al. Anticancer Res. 2009 Mar;29(3):797-807. Anticancer Res. 2009. PMID: 19414312 Review. - Radiation and new molecular agents, part II: targeting HDAC, HSP90, IGF-1R, PI3K, and Ras.
Chinnaiyan P, Allen GW, Harari PM. Chinnaiyan P, et al. Semin Radiat Oncol. 2006 Jan;16(1):59-64. doi: 10.1016/j.semradonc.2005.08.008. Semin Radiat Oncol. 2006. PMID: 16378908 Review.
Cited by
- Targeting EGFR Exon 20 Insertion Mutations in Non-small-Cell Lung Cancer: Changes in Treatment Strategies are Coming.
Liu H, Qin J, Qian X. Liu H, et al. Cancer Control. 2024 Jan-Dec;31:10732748241292782. doi: 10.1177/10732748241292782. Cancer Control. 2024. PMID: 39417568 Free PMC article. Review. - HSP90 inhibition suppresses tumor glycolytic flux to potentiate the therapeutic efficacy of radiotherapy for head and neck cancer.
Chen F, Tang C, Yang F, Ekpenyong A, Qin R, Xie J, Momen-Heravi F, Saba NF, Teng Y. Chen F, et al. Sci Adv. 2024 Feb 23;10(8):eadk3663. doi: 10.1126/sciadv.adk3663. Epub 2024 Feb 23. Sci Adv. 2024. PMID: 38394204 Free PMC article. - HSP90AA1 promotes lymphatic metastasis of hypopharyngeal squamous cell carcinoma by regulating epithelial-mesenchymal transition.
Tang F, Li Y, Pan M, Wang Z, Lu T, Liu C, Zhou X, Hu G. Tang F, et al. Oncol Res. 2023 Jul 21;31(5):787-803. doi: 10.32604/or.2023.030081. eCollection 2023. Oncol Res. 2023. PMID: 37547757 Free PMC article. - HSP90 facilitates stemness and enhances glycolysis in glioma cells.
Kang X, Chen J, Hou JF. Kang X, et al. BMC Neurol. 2022 Nov 11;22(1):420. doi: 10.1186/s12883-022-02924-7. BMC Neurol. 2022. PMID: 36368999 Free PMC article. - Targeting Heat Shock Proteins in Malignant Brain Tumors: From Basic Research to Clinical Trials.
Babi A, Menlibayeva K, Bex T, Doskaliev A, Akshulakov S, Shevtsov M. Babi A, et al. Cancers (Basel). 2022 Nov 4;14(21):5435. doi: 10.3390/cancers14215435. Cancers (Basel). 2022. PMID: 36358853 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous